Perelel just secured a fresh $27M growth round, and it lands like a seismic tap on the shoulder of an industry that keeps pretending women’s health is some side quest. Prelude Growth Partners led the raise, with Unilever Ventures, Willow Growth Partners, and Selva Ventures backing the move, and the whole thing reads like a coalition betting on a future where stage specific care is the standard instead of the exception. When a company builds from lived experience, clinical rigor, and a refusal to cut corners, capital eventually stops circling and starts committing.
The origin story is cut from the kind of truth you cannot fake. Victoria Thain Gioia confronted a pregnancy complication tied to folic acid deficiency and realized the prenatal aisle was more marketing experiment than medical solution. Alex Taylor battled Hashimoto’s and discovered that transparency in supplements was treated like a luxury. Dr. Banafsheh Bayati brought the OBGYN expertise that turned frustration into formulation instead of theory. Together they built something the market did not just want but clearly needed, which is why demand did not creep, it surged.
Look at the numbers. Profitability inside 5 years. Revenue doubling annually. Growth sitting north of 200% year over year. Nearly 3,500 capsules consumed every hour. 31M capsules sold in the 12 months ending early 2024, 48M by October 2024, 67M in 2023 alone, and by 2025 the pace hit roughly 182,000 vitamins a day. One third of customers returning for pregnancy round 2 and 3. These metrics do not whisper momentum. They shout product market fit in surround sound.
The investor bench is equally dialed in. Prelude Growth Partners, co-founded by Neda Daneshzadeh and Alicia Sontag, saw the blend of doctor founded credibility and clinical validation and moved fast. Unilever Ventures, with Rachel Harris and Isabelle Hemington guiding the deal, has been in since the seed days. Willow Growth Partners, led by Deborah Benton and Amanda Schutzbank, understood the consumer shift early. Selva Ventures, with Madeline Kaplan as Board Observer, recognized the long term upside in women’s wellness before it became fashionable. When this many sharp operators align, the trajectory usually bends upward.
What makes this round different is the scale of the ambition behind it. Perelel is moving beyond prenatal into full spectrum hormonal support, backed by cGMP manufacturing, Purity Awards, bioavailable formulations, and a 10M commitment to women’s health research. The partnerships with Magee-Womens Research Institute, Good+Foundation, and The Hope Project reinforce that this is not a brand trying to look scientific, it is a brand building the science. Add the LOOM acquisition and a leadership team that includes Victoria Dawson Hoff, Becky Kong, Lauren McMahon, Kayla Gregg, Kayte Angell, Linda Yon, Alexis Guss, and Madeline Sensibile, and you get a company scaling with intention instead of ego.
Startups Startup Funding Venture Capital Women Health Healthcare Health Tech Wellness Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring
